Last Week Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings

May 17, 2018 - By Matthew Richard

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 0.53, from 2017Q3’s 1.73. The ratio is negative due to Aerie Pharmaceuticals, Inc. positioning: 23 sold and 48 reduced. 21 funds amassed holdings and 64 increased holdings. Investors holded 34.42 million in 2017Q3 but now own 34.86 million shares or 1.29% more.
Granite Point Capital Mgmt Limited Partnership reported 46,000 shs or 0.27% of all its holdings. Tiaa Cref Investment Mgmt Limited Liability Corp has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Suffolk Cap Management Lc holds 1.98% or 255,449 shs in its capital. Credit Suisse Ag holds 179,503 shs or 0.01% of its capital. 455,427 were accumulated by Waddell Reed. Thrivent Fincl For Lutherans invested 0.02% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Mufg Americas Corp holds 0% or 395 shs. Harvey stated it has 23,519 shs or 0.51% of all its holdings. Moreover, Stifel has 0.02% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). C Worldwide Grp Hldgs A S, a Denmark-based fund reported 82,188 shs. Legal General Gru Public Limited Co accumulated 14,512 shs. Qs Ltd Liability Co accumulated 0% or 2,100 shs. State Board Of Administration Of Florida Retirement System reported 17,088 shs stake. Neuberger Berman Group Llc invested in 0.02% or 261,500 shs. Walleye Trading Ltd Liability invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AERI) has 100% bullish analysts. 11 are the (NASDAQ:AERI)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by Cantor Fitzgerald on Wednesday, February 28. On Tuesday, January 2 the firm earned “Buy” rating by Stifel Nicolaus. The stock rating was maintained by Mizuho with “Buy” on Wednesday, May 9. On Thursday, March 1 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, February 16 H.C. Wainwright reinitiated the shares of AERI in report with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Monday, December 18. On Wednesday, January 24 the company was maintained by Canaccord Genuity. On Wednesday, May 9 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright. On Thursday, March 29 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Mizuho. On Tuesday, May 8 the firm has “Buy” rating by Cantor Fitzgerald given. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

Ticker’s shares touched $51.15 during the last trading session after 0.10% change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has also 226,563 shares volume. AERI outperformed the S&P500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.02 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news brought out briefly go to: Gurufocus.com, Benzinga.com, Globenewswire.com, Businesswire.com or Benzinga.com. The titles are as follows: “9 Stocks Ron Baron Continues to Buy” brought out on May 17, 2018, “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” on May 08, 2018, “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …” with a publish date: May 03, 2018, “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” and the last “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: May 15, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.